Heart Failure Treatment with Beta-Blockers and Other Medications

Initial Pharmacological Approach for HFrEF

• The European Society of Cardiology recommends ensuring the patient is relatively stable without intravenous inotropic support or marked fluid retention before initiating beta-blockers 1
• The European Society of Cardiology suggests starting with very low doses of beta-blockers and doubling every 1-2 weeks if tolerated, targeting maintenance doses from large trials 1
• If worsening symptoms occur during beta-blocker titration, the European Society of Cardiology recommends first increasing diuretics or ACE inhibitors before reducing beta-blocker dose 1
• For hypotension during beta-blocker titration, the European Society of Cardiology advises reducing vasodilators first rather than the beta-blocker 1
• The European Society of Cardiology recommends referring patients to specialist care for severe heart failure, bradycardia, low blood pressure, or suspected asthma/bronchial disease 1
• The European Society of Cardiology suggests adding spironolactone in advanced heart failure despite ACE inhibitor and diuretic therapy, starting with 25 mg daily if serum potassium is less than 5.0 mmol/L and creatinine is less than 250 μmol/L 1
• The European Society of Cardiology recommends checking potassium and creatinine after 4-6 days of spironolactone initiation 1
• If potassium levels are elevated, the European Society of Cardiology advises reducing the spironolactone dose by 50% or stopping it if persistently elevated 1
• The European Society of Cardiology suggests reserving digoxin for patients in sinus rhythm with persistent symptoms despite ACE inhibitor and diuretic treatment, with a usual dose of 0.25-0.375 mg daily 1
• The European Society of Cardiology recommends avoiding digoxin in patients with bradycardia, second- or third-degree AV block, sick sinus syndrome, and electrolyte abnormalities 1
• The European Society of Cardiology advises against combining ACE inhibitors, ARBs, and MRAs due to increased risk of renal dysfunction and hyperkalemia, although this is not directly cited in the provided reference, beta-blocker absolute contraindications include asthma bronchiale, severe bronchial disease, symptomatic bradycardia or hypotension 1
• If inotropic support is needed in a patient on beta-blockade, the European Society of Cardiology recommends using phosphodiesterase inhibitors as their effects are not antagonized by beta-blockers 1

Treatment of Heart Failure Based on Ejection Fraction

Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤40%)

• The American College of Cardiology recommends that all patients with HFrEF receive four medication classes simultaneously, including ARNI/ACEi/ARB, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, to reduce mortality and hospitalization 2, 3
• The European Society of Cardiology suggests that beta-blockers, such as carvedilol, metoprolol succinate, or bisoprolol, reduce mortality by at least 20% and should be initiated in stable patients on background ACE inhibition 3, 4, 5
• Mineralocorticoid Receptor Antagonists (MRA) like spironolactone improve survival and morbidity, particularly in NYHA Class III-IV heart failure, and should be monitored closely for serum potassium and creatinine levels 4, 5
• SGLT2 Inhibitors represent the fourth pillar of therapy and should be initiated early regardless of diabetes status, reducing cardiovascular death and heart failure hospitalization 2, 6

Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF, LVEF 41-49%)

• The American College of Cardiology and the European Society of Cardiology recommend treating HFmrEF similarly to HFrEF with the same four-drug foundational therapy, though the evidence level is lower 6, 2

Heart Failure with Preserved Ejection Fraction (HFpEF, LVEF ≥50%)

• The American College of Cardiology suggests that SGLT2 inhibitors are the cornerstone of HFpEF treatment, reducing cardiovascular death and heart failure hospitalization 2, 6

Universal Management Principles Across All EF Categories

• The European Society of Cardiology recommends controlling sodium intake, avoiding excessive fluids and alcohol, and exercising regularly to improve exercise tolerance and quality of life 4, 7, 8
• Team-based care with cardiologists, primary care physicians, nurses, and pharmacists reduces mortality and hospitalization 8, 9